Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Leukemia 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 27Burkitt Lymphoma 27Lymphoma, Non-Hodgkin 22Lymphoma, Large B-Cell, Diffuse 22Myelodysplastic Syndromes 20Leukemia, Myeloid, Chronic-Phase 20Lymphoma, Follicular 19Leukemia, Lymphocytic, Chronic, B-Cell 18Leukemia, Myeloid, Accelerated Phase 17Multiple Myeloma 16Lymphoma, Large-Cell, Immunoblastic 15Blast Crisis 15Myeloproliferative Disorders 14Leukemia, Myeloid, Acute 14Dendritic Cell Sarcoma, Interdigitating 14Recurrence 13Lymphoma, Mantle-Cell 13Lymphoma, B-Cell, Marginal Zone 13Graft vs Host Disease 13Leukemia, Myelomonocytic, Chronic 12Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 12Hodgkin Disease 11Congenital Abnormalities 11Neoplasms, Plasma Cell 10Myelodysplastic-Myeloproliferative Diseases 10Anemia, Refractory, with Excess of Blasts 9Primary Myelofibrosis 8Lymphoma, Large-Cell, Anaplastic 8

Interventions

aldesleukin 16Cyclophosphamide 14fludarabine phosphate 11Interleukin-2 11fludarabine 10Nivolumab 7pembrolizumab 5cemiplimab 5Ipilimumab 5Temozolomide 4Fluorouracil 4Aminolevulinic Acid 4sonidegib 3Surgical Procedures, Operative 3Radiotherapy 3zanolimumab 2trametinib 2talabostat 2montanide ISA 51 2dabrafenib 2Whole-Body Irradiation 2Tablets 2Semaxinib 2Radiation 2Petrolatum 2Peptides 2MART-1 Antigen 2Gefitinib 2Eflornithine 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Skin Neoplasms × Methylprednisolone × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡